ClinicalTrials.gg
RecruitingNCT05841563Updated Sep 24, 2025

Clinical Trial of PM54 in Advanced Solid Tumors Patients.

A Phase 1 interventional study of PM54 in Advanced Solid Tumor, sponsored by PharmaMar. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by PharmaMar · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
125
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The first part of the study (phase Ia - dose escalation) will evaluate the safety and tolerability and identify the dose-limiting toxicities (DLTs) of PM54.

The second part of the study (phase Ib - safety run-in and expansion) will be to reassess the maximum tolerated dose (MTD) defined in the Phase Ia stage in a framework of more extensive premedication, and to evaluate the antitumor activity of PM54 according to the RECIST v.1.1 (or mRECIST v.1.1 in case of MPM) and/or serum markers as appropriate, in patients with selected advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumor

Keywords

  • Advanced Solid Tumor
03

In context

Lead sponsor

PharmaMar is the lead sponsor of 50 studies on the registry; 5 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily signed and dated written , obtained prior to any specific study procedure.
  2. Age ≥18 years.
  3. (ECOG) performance status (PS) ≤1.
  4. Phase Ia (dose escalation) stage: patients must have:

    1. confirmed diagnosis of advanced solid tumors for whom no standard therapy exists:

      • Genitourinary tract tumors: urothelial carcinoma, clear cell renal carcinoma and prostate adenocarcinoma.
      • Cutaneous melanoma.
      • Gastrointestinal: esophageal adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, and poorly differentiated (grade 3) gastroenteropancreatic Neuroendocrine Carcinoma (NEC )with Ki67 index >55%.
      • Lung: non-small cell lung cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
      • Gynecological tumors: epithelial ovarian carcinoma (including primary peritoneal disease and/or fallopian tube carcinomas), endometrial adenocarcinoma and carcinoma of cervix.
      • Breast: ductal or lobular.
      • Sarcoma: liposarcoma, leiomyosarcoma, synovial sarcoma and Ewing sarcoma.
      • Deleterious germline BRCA1/2 mutation tumors.
      • Other: MPM, extrapulmonary small cell carcinoma, adrenocortical carcinoma.

      Note: patients with measurable or non- according to the (RECIST) v.1.1 (or v.1.1 in case of MPM) are eligible during this stage.

    2. No more than three .
  5. Phase Ib (safety run-in and expansion) stage: patients must have:

    1. Pathologically confirmed diagnosis of one of the following:

      • Extrapulmonary small cell carcinoma) or poorly differentiated grade 3 gastroenteropancreatic NEC with Ki67 index ≥55%.
      • Cutaneous melanoma.
      • Malignant pleural mesothelioma (MPM).
      • Endometrial adenocarcinoma (Note: carcinosarcomas are not allowed).
      • Synovial sarcoma
    2. Measurable disease according to the RECIST v.1.1 (or mRECIST v.1.1 in case of MPM) and/or evaluable disease byserum markers in case of prostate and ovarian cancer (according to the Prostate-Specific Antigen Working Group Recommendations (PSAWGR) and the Gynecologic Cancer Intergroup (GCIG) specific criteria, respectively).
    3. Progressive disease after last therapy at study entry.
    4. Patients must have received standard treatments:

      • Extrapulomnary small cell carcinoma/ gastroenteropancreatic NEC: no more than two prior lines of chemotherapy.
      • Cutaneous melanoma:

        1. BRAF wild-type (WT) melanoma: at least one prior line of immunotherapy for advanced disease. The patient may have received this therapy in the setting. No more than two prior lines of systemic therapy for advanced disease. Note: patients with disease progression during adjuvant therapy or within the first six months after the last dose of adjuvant therapy will be considered as having been treated with one prior line of treatment.
        2. BRAF-mutated melanoma: at least one prior line of target therapy for advanced disease with BRAF inhibitor with or without MEK-inhibitor, and at least one prior line of immunotherapy for advanced disease. The patient may have received any of these therapies in the adjuvant setting. No more than three prior lines of systemic therapy for advanced disease.
      • Malignant pleural mesothelioma (MPM): no more than two prior lines of therapy; one of them should be a platinum containing line. Patients with non-epithelioid MPM should have received a prior immunotherapy line.
      • Endometrial adenocarcinoma: no more than two prior lines of chemotherapy for disease. In addition, regardless of setting, patients must have received one prior platinum-containing regimen.
      • Synovial sarcoma: at least one but no more than two prior lines of chemotherapy.
  6. Recovery to grade ≤1 from drug-related AEs of previous treatments, excluding grade 2 alopecia, according to the v.5.
  7. Laboratory values within seven days prior to first infusion:

    1. (ANC) ≥1.5 x 10\^9/L, count ≥100 x 10\^9/L and ≥9 g/dL (patients may be transfused for anemia as clinically indicated prior to study entry).
    2. (AST) and Alanine Aminotransferase (ALT) ≤3.0 x .
    3. Total ≤upper limit of normal (ULN) (up to 1.5 x ULN for patients with Gilbert's syndrome).
    4. ≥30 mL/min (calculated using the Cockcroft and Gault's formula).
    5. Serum albumin ≥3 g/dL. *
    6. Creatine phosphokinase (CPK) ≤ 2.5 x ULN.
  8. :

    1. At least three weeks since the last chemotherapy.
    2. At least four weeks since the last monoclonal antibody (MAb)-containing therapy.
    3. At least two weeks since the last biological/ single-agent therapy (excluding MAbs) and/or palliative radiotherapy (RT).
    4. In patients with hormone-sensitive breast cancer progressing while on hormone therapy (except for luteinizing hormone-releasing hormone [LHRH] analogues in pre-menopausal women or megestrol acetate), all other hormonal therapies must be stopped at least one week before study treatment start.
    5. Castrate-resistant prostate cancer (CRPC) patients may continue receiving hormone therapy prior to and during study treatment. Note: washout periods will be referred to the day of first cycle administration (Day 1), not to the day of registration.
  9. Evidence of non-childbearing status for women of (WOCBP). WOCBP must agree to use a highly effective measure during the course of the trial and up to seven months after the last study drug infusion. Fertile male patients with WOCBP partners should use condoms during treatment and for four months following the last study drug infusion.

    • Albumin infusion to increase the blood level in order to fulfill the inclusion criterion is strictly forbidden.

Exclusion criteria

Exclusion Criteria:

For both stages:

  1. Concomitant diseases/conditions:

    1. Increased cardiac risk:

      • Uncontrolled arterial hypertension despite optimal management (≥160/100 mmHg).
      • Presence of valvular disease.
      • History of long syndrome.
      • Corrected QT interval (QTcF, Fridericia correction) ≥450 ms on screening .
      • History of ischemic heart disease, including myocardial infarction, unstable angina, coronary arteriography or cardiac stress testing with findings consistent with coronary occlusion or infarction ≤6 months prior to study entry.
      • History of heart failure or left ventricular dysfunction ( [LVEF] ≤50%) by multiple-gated acquisition scan (MUGA) or echocardiography (ECHO).
      • Clinically relevant ECG abnormalities, including any of the following: right bundle branch block with left anterior hemiblock, second (Mobitz II) or third degree atrioventricular block.
      • Symptomatic arrhythmia.
      • Concomitant medication with risk of inducing torsades de pointes, which cannot be discontinued or switched to an alternative drug prior to start PM54 dosing.
      • Use of a cardiac pacemaker.
    2. Active infection requiring systemic treatment.
    3. Known (HIV) or known chronic active hepatitis. For , this includes positive tests for both Hepatitis B surface antigen and quantitative Hepatitis B polymerase chain reaction (PCR). For , this includes positive tests for both Hepatitis C antibody and quantitative Hepatitis C PCR.
    4. Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patient's participation in this study (e.g., COVID-19).
  2. Symptomatic, -requiring, and progressing central nervous system (CNS) disease. Exceptions will be made for patients who have completed radiotherapy at least four weeks prior to inclusion (asymptomatic patients taking steroids in the process of already being tapered within two weeks prior to inclusion).
  3. Patients with carcinomatous meningitis.
  4. Prior bone marrow or stem cell transplantation.
  5. Prior treatment with trabectedin, lurbinectedin, or ecubectedin (PM14).
  6. Use of (strong or moderate) inhibitors or strong inducers of activity within two weeks prior to the first infusion of PM54.
  7. Known to any of the components of the drug product.
  8. Limitation of the patient's ability to comply with the treatment or to follow the protocol procedures.
  9. Women who are pregnant or breast feeding and fertile patients (men and women) who are not using a highly effective method of (see inclusion criterion No. 9).
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
125 participants (estimated)

Study arms

  • Experimental
    PM54

    Phase Ia (dose escalation) stage: Patients will receive PM54 i.v. at a starting dose of 0.3 mg/m2. Phase Ib (safety run-in) stage: The maximum tolerated dose (MTD) of PM54 previously defined in Phase Ia will be reassessed. Phase Ib (expansion) stage: Patients will receive PM54 i.v. at the recommended dose selected after the safety run-in stage.

    Drug: PM54

Interventions

  • DrugPM54

    PM54 powder for concentrate for solution for infusion (3 mg/vial) is a sterile, preservative-free, lyophilized white to yellowish cake in a single-dose vial for reconstitution prior to intravenous infusion. Each vial contains 3 mg PM54. Route of administration: Intravenous infusion

06

What researchers measure

Primary outcomes

  1. Phase 1a (dose escalation) and Phase1b (safety run-in): Dose-limiting toxicities (DLTs)

    Time frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)

  2. Phase 1a (dose escalation) and Phase1b (safety run-in): Treatment-emergent Adverse Events (TEAEs)

    Time frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)

  3. Phase 1a (dose escalation) and Phase1b (safety run-in): Drug-related Adverse Events (AEs)

    Time frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)

  4. Phase 1a (dose escalation) and Phase1b (safety run-in): Drug-related deaths

    Time frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)

  5. Phase 1a (dose escalation) and Phase1b (safety run-in): Serious adverse events (SAEs)

    Time frame: Screening up to end of first cycle of treatment (Cycle 1 is 21 days)

  6. Phase 1a (dose escalation) and Phase1b (safety run-in): Drug-related delays

    Time frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)

  7. Phase 1a (dose escalation) and Phase1b (safety run-in): Dose reductions

    Time frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)

  8. Phase 1a (dose escalation) and Phase1b (safety run-in): Treatment discontinuations

    Time frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)

  9. Phase 1a (dose escalation) and Phase1b (safety run-in): Maximum tolerated dose (MTD)

    Lowest dose level explored during dose escalation in which one third (i.e., 33%) or more of evaluable patients develop a DLT in Cycle 1.

    Time frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)

  10. Phase 1a (dose escalation) and Phase1b (safety run-in): Recommended dose (RD)

    Once the maximum tolerated dose (MTD) is reached, lower dose level will be confirmed as the RD if less than one third (i.e., 33%) of at least nine fully evaluable patients at that dose level develop DLT during Cycle 1.

    Time frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)

  11. Phase1b (safety run-in): Determination of RD with more extensive premedication

    A dose level will be confirmed as the RD with more extensive premedication if less than one third (i.e., 33%) of at least nine fully evaluable patients at that dose level develop DLT during Cycle 1.

    Time frame: Day 1 Cycle 1 up to end of first cycle of treatment (Cycle 1 is 21 days)

  12. Phase 1b (expansion): Antitumor activity

    Antitumor activity, evaluated according to the RECIST v.1.1 (or mRECIST v.1.1 in case of MPM) and serum markers, as appropriate.

    Time frame: Every 6 weeks (± 1 week) in all patients with evaluable disease until Cycle 6. For patients continuing treatment after Cycle 6, assessments performed every 9 weeks (± 1 week) while on treatment, unless otherwise indicated (Up to 48 months)

Secondary outcomes

  1. Phase 1b (expansion): Adverse events (AEs)

    AEs will be graded according to the NCI-CTCAE v.5.

    Time frame: Screening to end of study (up to approximately 48 months)

  2. Phase 1b (expansion): Treatment discontinuation

    Time frame: Day 1 up to end of study (up to approximately 48 months)

  3. Phase 1b (expansion): Dose reductions

    Time frame: Day 1 up to end of study (up to approximately 48 months)

  4. Phase 1b (expansion): Treatment delays due to adverse events (AEs)

    Time frame: Day 1 up to end of study (up to approximately 48 months)

  5. Phase 1a (dose escalation) and Phase 1b (safety run-in): QT Assessment

    The QT assessment will evaluate the risk of prolongation of the QT interval by PM54.

    Time frame: Day 1 of Cycle 1 for all patients participating in the QT assessment, and on Day 1 of Cycle 2 for patients treated during the Phase Ia stage once the MTD has been determined, will be used in this substudy.

  6. Phase 1a (dose escalation) and Phase 1b (safety run-in): Maximum Plasma Concentration (Cmax)

    Time frame: Cycle 1 and Cycle 2 during the Phase Ia (dose expansion) stage once the MTD has been determined. Each cycle is 21 days.

  7. Phase 1a (dose escalation) and Phase 1b (safety run-in): Concentration in urine samples

    Time frame: Day 1 of Cycle 1 and Cycle 2 during the Phase Ia (dose expansion) stage once the MTD has been determined. Each Cycle is 21 days.

  8. Phase 1b (safety run-in and dose expansion): Percentage of patients with clinical benefit (overall response rate (ORR) or stable disease (SD) ≥4 months associated with tumor shrinkage)

    Time frame: Day 1 up to end of study (up to approximately 48 months)

  9. Phase 1b (safety run-in and dose expansion): Response rate

    Response rate defined as percentage of patients with partial response (PR), with complete response (CR), or the sum of both \[overall response rate (ORR)\].

    Time frame: Day 1 up to end of study (up to approximately 48 months)

  10. Phase 1b (safety run-in and dose expansion): Percentage of patients with stable disease (SD) ≥4 months

    Time frame: Day 1 up to end of study (up to approximately 48 months)

  11. Phase 1b (safety run-in and dose expansion): Duration of Response (DoR)

    Time frame: From the date of the first documentation of response to the date of documented progression or death, assessed up to 48 months

  12. Phase 1b (safety run-in and dose expansion): Progression-free Survival (PFS)

    Time frame: From the date of first infusion of study treatment to the date of first documented progression or date of death from any cause, assessed up to 48 months

  13. Phase 1b (safety run-in and dose expansion): Overall survival (OS)

    Time frame: From the date of first infusion of study treatment to the date of death (due to any cause) or last contact (in this case, survival will be censored on the date of last contact), assessed up to 48 months

07

Study locations

3 of 3 sites recruiting
  • South Texas Accelerated Research Therapeutics
    San Antonio, Texas 78229-3307, United States
    Recruiting
    • Kyriakos P Papadopoulos · Contact
  • Institut Jules Bordet
    Anderlecht, 1070, Belgium
    Recruiting
    • Nuria Kotecki · Contact
  • HM Universitario Sanchinarro
    Madrid, M 28050, Spain
    Recruiting
    • Maria-Jose de Miguel-Luken · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2023 (actual). Primary completion is estimated for Dec 2026, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2023
First posted
May 3, 2023
StartActual
Apr 28, 2023
Primary completionEst.
Dec 30, 2026
CompletionEst.
Apr 30, 2027
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05841563
Lead sponsor
PharmaMar
Responsible party
Sponsor
First posted
May 3, 2023
Start date
Apr 28, 2023
Primary completion
Dec 30, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Sep 24, 2025

Study contacts

Cristian M Fernández, M.D.
Contact
cmfernandez@pharmamar.com
+ 34 91 846 6077
Gaston Federico Boggio, M.D.
Contact
gfboggio@pharmamar.com
+34 91 823 4524

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion